Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,069 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Energy metabolism dysregulation, cerebrovascular aging, and time-restricted eating: Current evidence and proof-of-concept findings.
da C Pinaffi-Langley AC, Pinto CB, Mukli P, Peterfi A, Kaposzta Z, Owens CD, Szarvas Z, Muranyi M, Adams C, Shahriari A, Balasubramanian P, Ungvari Z, Csiszar A, Conley S, Hord NG, Anderson L, Tarantini S, Yabluchanskiy A. da C Pinaffi-Langley AC, et al. Among authors: owens cd. PNAS Nexus. 2024 Nov 8;3(11):pgae505. doi: 10.1093/pnasnexus/pgae505. eCollection 2024 Nov. PNAS Nexus. 2024. PMID: 39584020 Free PMC article. Review.
Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation.
Kumar A, Soumerai JD, Abramson JS, Barnes JA, Caron PC, Chhabra S, Chabowska M, Dogan A, Falchi L, Grieve C, Haydu JE, Johnson PC, Joseph A, Kelly H, Labarre A, Lue JK, Martignetti R, Mi J, Moskowitz AJ, Owens CN, Plummer S, Puccio M, Salles GA, Seshan VE, Simkins E, Slupe N, Zhang H, Zelenetz AD. Kumar A, et al. Among authors: owens cn. Blood. 2024 Oct 22:blood.2024025563. doi: 10.1182/blood.2024025563. Online ahead of print. Blood. 2024. PMID: 39437708
Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94].
Fitzgerald KN, Lee CH, Voss MH, Carlo MI, Knezevic A, Peralta L, Chen Y, Lefkowitz RA, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha RR, Feldman DR, Motzer RJ. Fitzgerald KN, et al. Among authors: owens cn. Eur Urol. 2024 Oct 18:S0302-2838(24)02643-5. doi: 10.1016/j.eururo.2024.10.002. Online ahead of print. Eur Urol. 2024. PMID: 39426859 No abstract available.
Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience.
Cassanello G, Drill E, Rivas-Delgado A, Okwali M, Isgor I, Caron PC, Epstein-Peterson Z, Ghione P, Hamlin P, Lue J, Horwitz SM, Intlekofer AM, Johnson W, Kumar A, Moskowitz A, Noy A, Owens C, Palomba LM, Torka P, Galera P, Zelenetz AD, Salles G, Falchi L. Cassanello G, et al. Among authors: owens c. Haematologica. 2024 Sep 5. doi: 10.3324/haematol.2024.285600. Online ahead of print. Haematologica. 2024. PMID: 39234863 Free article.
1,069 results